Published in BJU Int on September 01, 2005
Tissue engineering as a potential alternative or adjunct to surgical reconstruction in treating pelvic organ prolapse. Int Urogynecol J (2012) 3.39
Increased duration of simulated childbirth injuries results in increased time to recovery. Am J Physiol Regul Integr Comp Physiol (2007) 1.26
Multilayer tendon slices seeded with bone marrow stromal cells: a novel composite for tendon engineering. J Orthop Res (2009) 1.16
Animal models of female stress urinary incontinence. J Urol (2008) 1.08
Engineered tendon with decellularized xenotendon slices and bone marrow stromal cells: an in vivo animal study. J Tissue Eng Regen Med (2011) 0.93
Postpartum stress urinary incontinence: lessons from animal models. Expert Rev Obstet Gynecol (2010) 0.91
Animal models of stress urinary incontinence. Handb Exp Pharmacol (2011) 0.89
Human umbilical cord blood mononuclear cell transplantation in rats with intrinsic sphincter deficiency. J Korean Med Sci (2010) 0.83
Swimming: effects on stress urinary incontinence and the expression of nerve growth factor in rats following transabdominal urethrolysis. Int Neurourol J (2011) 0.83
Pubo-urethral ligament transection causes stress urinary incontinence in the female rat: a novel animal model of stress urinary incontinence. J Urol (2007) 0.81
Effect of Treadmill Exercise on Leak-point pressure and Neuronal Activation in Brain of Rats with Stress Urinary Incontinence. Int Neurourol J (2010) 0.77
Stem Cell Therapy for Treatment of Stress Urinary Incontinence: The Current Status and Challenges. Stem Cells Int (2016) 0.75
Evaluation of xenogenic extracellular matrices as adjuvant scaffolds for the treatment of stress urinary incontinence. Int Urogynecol J (2013) 0.75
Unroofed coronary sinus syndrome: diagnosis, classification, and surgical treatment. J Thorac Cardiovasc Surg (2003) 2.50
Intravesical botulinum toxin A administration inhibits COX-2 and EP4 expression and suppresses bladder hyperactivity in cyclophosphamide-induced cystitis in rats. Eur Urol (2008) 2.24
Comparison of doxazosin with or without tolterodine in men with symptomatic bladder outlet obstruction and an overactive bladder. BJU Int (2004) 2.11
Urologic complications of diabetes. Diabetes Care (2005) 2.03
Urinary nerve growth factor levels are elevated in patients with detrusor overactivity and decreased in responders to detrusor botulinum toxin-A injection. Eur Urol (2008) 1.96
Selective granulocyte and monocyte adsorptive apheresis as a first-line treatment for steroid naïve patients with active ulcerative colitis: a prospective uncontrolled study. Dig Dis Sci (2004) 1.92
Botulinum toxin type A improves benign prostatic hyperplasia symptoms in patients with small prostates. Urology (2005) 1.81
Single-institution experience in 110 patients with botulinum toxin A injection into bladder or urethra. Urology (2005) 1.77
Mechanisms underlying the recovery of lower urinary tract function following spinal cord injury. Prog Brain Res (2006) 1.74
Cholesterol-modified polyurethane valve cusps demonstrate blood outgrowth endothelial cell adhesion post-seeding in vitro and in vivo. Ann Thorac Surg (2006) 1.63
Novel action of botulinum toxin on the stromal and epithelial components of the prostate gland. J Urol (2006) 1.62
Vascular endothelial growth factor in children with congenital heart disease. Ann Thorac Surg (2003) 1.57
A saddle-shaped annulus reduces systolic strain on the central region of the mitral valve anterior leaflet. J Thorac Cardiovasc Surg (2007) 1.56
Recent advances in understanding the biology of diabetes-associated bladder complications and novel therapy. BJU Int (2005) 1.56
How sacral nerve stimulation neuromodulation works. Urol Clin North Am (2005) 1.55
Future direction in pharmacotherapy for non-neurogenic male lower urinary tract symptoms. Eur Urol (2013) 1.54
Nerve growth factor level in the prostatic fluid of patients with chronic prostatitis/chronic pelvic pain syndrome is correlated with symptom severity and response to treatment. BJU Int (2010) 1.52
Association of overactive bladder and C-reactive protein levels. Results from the Boston Area Community Health (BACH) Survey. BJU Int (2011) 1.50
Bladder overactivity and hyperexcitability of bladder afferent neurons after intrathecal delivery of nerve growth factor in rats. J Neurosci (2006) 1.48
Pathophysiology of urinary incontinence in murine models. Int J Urol (2012) 1.48
Ventricular septal dysfunction after surgical closure of multiple ventricular septal defects. Ann Thorac Surg (2013) 1.47
Appropriate additional pulmonary blood flow at the bidirectional Glenn procedure is useful for completion of total cavopulmonary connection. Ann Thorac Surg (2005) 1.47
Current and future pharmacological treatment for overactive bladder. J Urol (2002) 1.47
Transabdominal ultrasonography of detrusor wall thickness in women with overactive bladder. BJU Int (2009) 1.46
Effect of botulinum toxin A on urothelial-release of ATP and expression of SNARE targets within the urothelium. Neurourol Urodyn (2013) 1.46
Emerging role of botulinum toxin in the treatment of neurogenic and non-neurogenic voiding dysfunction. Curr Urol Rep (2002) 1.44
Pharmacokinetics, metabolism, and saliva output during transdermal and extended-release oral oxybutynin administration in healthy subjects. Mayo Clin Proc (2003) 1.43
Afferent nerve regulation of bladder function in health and disease. Handb Exp Pharmacol (2009) 1.42
Urine cytokines suggest an inflammatory response in the overactive bladder: a pilot study. Int Urol Nephrol (2009) 1.41
Immunoneutralization of nerve growth factor in lumbosacral spinal cord reduces bladder hyperreflexia in spinal cord injured rats. J Urol (2002) 1.41
Sustained beneficial effects of intraprostatic botulinum toxin type A on lower urinary tract symptoms and quality of life in men with benign prostatic hyperplasia. BJU Int (2006) 1.40
Inhibitory role of the spinal galanin system in the control of micturition. Urology (2013) 1.39
Orchiopexy after prior inguinal surgery: a distal approach. J Urol (2011) 1.39
An infected pseudoaneurysm following a modified Blalock-Taussig shunt. Interact Cardiovasc Thorac Surg (2008) 1.39
Cool (TRPM8) and hot (TRPV1) receptors in the bladder and male genital tract. J Urol (2004) 1.36
Urethral closure mechanisms under sneeze-induced stress condition in rats: a new animal model for evaluation of stress urinary incontinence. Am J Physiol Regul Integr Comp Physiol (2003) 1.32
Transmembrane interaction mediates complex formation between peptidase homologues and Kv4 channels. Mol Cell Neurosci (2005) 1.30
Adacolumn for selective leukocytapheresis as a non-pharmacological treatment for patients with disorders of the immune system: an adjunct or an alternative to drug therapy? J Clin Apher (2005) 1.30
The role of bladder-to-urethral reflexes in urinary continence mechanisms in rats. Am J Physiol Renal Physiol (2004) 1.29
Urinary nerve growth factor level is increased in patients with interstitial cystitis/bladder pain syndrome and decreased in responders to treatment. BJU Int (2009) 1.28
Rehabilitation and medical management of the adult with spina bifida. Am J Phys Med Rehabil (2008) 1.26
Changes in afferent activity after spinal cord injury. Neurourol Urodyn (2010) 1.26
Nerve growth factor in bladder dysfunction: contributing factor, biomarker, and therapeutic target. Neurourol Urodyn (2011) 1.25
Therapeutic receptor targets for lower urinary tract dysfunction. Naunyn Schmiedebergs Arch Pharmacol (2007) 1.25
Inhibitory and excitatory perigenital-to-bladder spinal reflexes in the cat. Am J Physiol Renal Physiol (2007) 1.25
An open-label prospective randomized multicenter study shows very rapid remission of ulcerative colitis by intensive granulocyte and monocyte adsorptive apheresis as compared with routine weekly treatment. Am J Gastroenterol (2009) 1.24
Suppression of detrusor-sphincter dyssynergia by immunoneutralization of nerve growth factor in lumbosacral spinal cord in spinal cord injured rats. J Urol (2004) 1.24
Efficacy of a criterion-driven transfusion protocol in patients having pediatric cardiac surgery. J Thorac Cardiovasc Surg (2004) 1.22
The application of botulinum toxin in the prostate. J Urol (2006) 1.22
Improved sphincter contractility after allogenic muscle-derived progenitor cell injection into the denervated rat urethra. Urology (2003) 1.21
Fiber kinematics of small intestinal submucosa under biaxial and uniaxial stretch. J Biomech Eng (2006) 1.20
Effect of duloxetine, a norepinephrine and serotonin reuptake inhibitor, on sneeze-induced urethral continence reflex in rats. Am J Physiol Renal Physiol (2008) 1.20
Identification of c-kit-positive cells in the mouse ureter: the interstitial cells of Cajal of the urinary tract. Am J Physiol Renal Physiol (2003) 1.19
Treatment of interstitial cystitis. Urology (2004) 1.19
Evaluation of heart fatty acid-binding protein as a rapid indicator for assessment of myocardial damage in pediatric cardiac surgery. J Thorac Cardiovasc Surg (2004) 1.18
Role of noradrenergic pathways in sneeze-induced urethral continence reflex in rats. Am J Physiol Renal Physiol (2006) 1.18
Simultaneous repair of pectus excavatum and congenital heart disease over the past 30 years. Eur J Cardiothorac Surg (2002) 1.18
Decrease of urinary nerve growth factor levels after antimuscarinic therapy in patients with overactive bladder. BJU Int (2009) 1.17
The other bladder syndrome: underactive bladder. Rev Urol (2013) 1.17
Delayed treatment of bladder outlet obstruction after sling surgery: association with irreversible bladder dysfunction. J Urol (2004) 1.17
Comparison of leak point pressure methods in an animal model of stress urinary incontinence. Int Urogynecol J Pelvic Floor Dysfunct (2005) 1.16
A comparative trial of psychotherapy and pharmacotherapy for "pure" dysthymic patients. J Affect Disord (2005) 1.13
Intravesical botulinum toxin a administration produces analgesia against acetic acid induced bladder pain responses in rats. J Urol (2004) 1.12
Botulinum toxin a has antinociceptive effects in treating interstitial cystitis. Urology (2004) 1.12
Effect of botulinum toxin A on the autonomic nervous system of the rat lower urinary tract. J Urol (2003) 1.10
Prevalence of overactive bladder and associated risk factors in 1359 patients with type 2 diabetes. Urology (2011) 1.10
Qualitative and quantitative expression profile of muscarinic receptors in human urothelium and detrusor. J Urol (2006) 1.10
Urodynamic and immunohistochemical evaluation of intravesical botulinum toxin A delivery using liposomes. J Urol (2009) 1.09
Reactive oxygen species mediate detrusor overactivity via sensitization of afferent pathway in the bladder of anaesthetized rats. BJU Int (2007) 1.09
Green onions: potential mechanism for hepatitis A contamination. J Food Prot (2006) 1.07
Multiplex analysis of urinary cytokine levels in rat model of cyclophosphamide-induced cystitis. Urology (2008) 1.07
Muscle derived stem cell therapy for stress urinary incontinence. World J Urol (2008) 1.06
Emerging role of botulinum toxin in the management of voiding dysfunction. J Urol (2004) 1.06
Differential expression of functional cannabinoid receptors in human bladder detrusor and urothelium. J Urol (2009) 1.05